Lorlatinib Renal Impairment Study

NCT03542305 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer